Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 21,275 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 21,275 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $27.67, for a total value of $588,679.25. Following the completion of the sale, the chief financial officer owned 164,853 shares of the company’s stock, valued at $4,561,482.51. This trade represents a 11.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Tuesday, July 7th, David Mountcastle sold 600 shares of Privia Health Group stock. The shares were sold at an average price of $27.57, for a total value of $16,542.00.
• On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The stock was sold at an average price of $27.50, for a total value of $680,185.00.
• On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The stock was sold at an average price of $25.18, for a total transaction of $432,995.28.
• On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total transaction of $76,501.00.
• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $179,690.37.

Privia Health Group Stock Up 1.5%

Shares of NASDAQ:PRVA opened at $27.89 on Tuesday. The company’s 50 day moving average price is $23.82 and its two-hundred day moving average price is $23.17. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $27.96. The firm has a market cap of $3.51 billion, a PE ratio of 174.32, a PEG ratio of 2.17 and a beta of 0.83.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. ArrowMark Colorado Holdings LLC increased its holdings in Privia Health Group by 139.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after purchasing an additional 489,866 shares in the last quarter. Algert Global LLC boosted its stake in shares of Privia Health Group by 277.4% during the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after purchasing an additional 355,966 shares in the last quarter. Freestone Grove Partners LP boosted its stake in shares of Privia Health Group by 40.6% during the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after purchasing an additional 350,194 shares in the last quarter. Renaissance Group LLC bought a new stake in shares of Privia Health Group during the fourth quarter worth about $7,776,000. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Privia Health Group by 93.3% during the second quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company’s stock worth $14,013,000 after purchasing an additional 294,101 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PRVA has been the topic of a number of analyst reports. Barclays reduced their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Zacks Research cut Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Canaccord Genuity Group cut their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Finally, Evercore set a $26.00 target price on Privia Health Group in a report on Wednesday, April 8th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.